Incubate Responds to President Trump's Most Favored Nation Drug Pricing Proposal in "Great Healthcare Plan"

WASHINGTON (January 15) -- Today, President Trump unveiled his "Great Healthcare Plan," including a proposal for Congress to codify Most Favored Nation (MFN) drug pricing into law. This policy would import foreign government price controls into the U.S. market and threaten the innovation ecosystem responsible for delivering new cures and lifesaving treatments. 

Incubate's executive director, John Stanford, issued the following statement in response to the announcement:

"Codifying Most Favored Nation drug pricing is bad policy. MFN is government price-setting by another name, tying Americans to drug prices based on foreign governments rather than a medicine's value in the U.S. market.

"Lawmakers should reject any effort to codify MFN, which would have immediate and far-reaching consequences for life sciences investment and research. In Incubate Policy Lab's 2026 Investor Survey, 87% of investors said federal price-setting policies such as MFN would reduce U.S. biotech investment. Codifying MFN will lead to fewer clinical trials, fewer cures, and weaken America's global position as a leader in biomedical innovation.

"Incubate is committed to educating policymakers on solutions that lower healthcare costs for Americans while ensuring the United States does not cede ground to China or other competitors in the race to develop the next generation of medicines."

To learn more about how policy is impacting investment in the life sciences, check out Incubate Policy Lab's 2026 Investor Survey.

###